Logo image
Ganciclovir-induced encephalopathy in a bone marrow transplant recipient
Journal article   Open access   Peer reviewed

Ganciclovir-induced encephalopathy in a bone marrow transplant recipient

A Sharathkumar and P. J Shaw
Bone marrow transplantation (Basingstoke), Vol.24(4), pp.421-423
1999
DOI: 10.1038/sj.bmt.1701933
PMID: 10467333
url
https://doi.org/10.1038/sj.bmt.1701933View
Published (Version of record) Open Access

Abstract

Ganciclovir is widely used as prophylactic and pre-emptive therapy, as well as treatment, for CMV infection following BMT. We report a case treated with ganciclovir 5 days a week. Following escalation of the ganciclovir dose to a twice daily dose to treat CMV antigenaemia, he developed encephalopathy. His encephalopathy resolved with withdrawal of ganciclovir. Ganciclovir encephalopathy has been described in other groups of patients but has not been reported following BMT to date. With its widespread use this complication is likely to be seen more often.
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone marrow, stem cells transplantation. Graft versus host reaction Drug toxicity and drugs side effects treatment Medical sciences Pharmacology. Drug treatments Toxicity: nervous system and muscle Transfusions. Complications. Transfusion reactions. Cell and gene therapy

Details

Metrics

Logo image